Tevogen Eyes CRO Acquisition Across 20 Countries to Add $20M Revenue
Tevogen is evaluating a niche CRO operating in more than 20 countries that could add over $20 million of annual revenue and support double-digit growth. The move advances its strategy to build a cash-flow-oriented healthcare enterprise with potential to reach $100 million in annual revenue through complementary acquisitions.
1. Advanced-Stage CRO Evaluation
Tevogen is in advanced-stage evaluation of a niche contract research organization operating across more than 20 countries with established expertise in oncology, rare diseases and medical devices. The potential transaction could add over $20 million in annual revenue and support double-digit growth.
2. Strategic Growth Objectives
This acquisition aligns with Tevogen’s goal to build a cash-flow-oriented healthcare enterprise by integrating complementary clinical research capabilities. Management projects the combined activities, alongside other acquisitions under review, could drive annual revenue toward $100 million.
3. Outlook and Next Steps
Tevogen expects to complete diligence and negotiate transaction terms in the coming months, then integrate the CRO’s global development infrastructure to enhance scalability. Further updates on revenue contributions and acquisition progress will follow once agreements are finalized.